Our jaundice Care Path for Zero Separation is not a one-size-fits-all approach. We collaborate closely with hospitals to create a tailored plan based on our blue print, ensuring smooth implementation.
With our patented technology at the core, we built the jaundice Care Path for Zero Separation. In co-creation with hospitals, we ensure a seamless transition to zero-separation phototherapy, integrating our wearable phototherapy into care pathways. Together with you, we transform phototherapy into a wearable, mobile solution, allowing parents to comfort their baby at home or in the maternity ward.
With our patented technology at the core, we built the jaundice Care Path for Zero Separation. In co-creation with hospitals, we ensure a seamless transition to zero-separation phototherapy, integrating our wearable phototherapy into care pathways. Together with you, we transform phototherapy into a wearable, mobile solution, allowing parents to comfort their baby at home or in the maternity ward.
We don’t just offer a device—we help hospitals implement the jaundice Care Path for Zero Separation. Our team works closely with your hospital to align stakeholders, optimize workflows, and tailor care processes to fit your hospital’s needs. With our expertise, hospitals reduce workload and accelerate the adoption of patient-centered jaundice care. Together we create your Care Path, based on our blue print.
We don’t just offer a device—we help hospitals implement the jaundice Care Path for Zero Separation. Our team works closely with your hospital to align stakeholders, optimize workflows, and tailor care processes to fit your hospital’s needs. With our expertise, hospitals reduce workload and accelerate the adoption of patient-centered jaundice care. Together we create your Care Path, based on our blue print.
At the core of our Care Path is our patented technology Jauni Wearable Phototherapy, designed for both hospital and home use. This ultra-light, mobile device replaces bulky, isolating treatment methods with an effective solution: easy to use, comfortable to wear, and uninterrupted clinically proven therapy. Babies stay secure in their parents' embrace while receiving clinically evaluated therapy. This not only reduces stress for newborns and parents but also helps hospitals save on nursing hours and incubator stays.
With trusted hospital-approved guidance, the Bilihome Remote Care App helps parents care for their newborn during treatment. It offers step-by-step instructions, safe device handling tips, and answers to common questions. Parents can log key health indicators, while healthcare staff monitor progress remotely—ensuring safe, supported home-based jaundice care.
At the core of our Care Path is our patented technology Jauni Wearable Phototherapy, designed for both hospital and home use. This ultra-light, mobile device replaces bulky, isolating treatment methods with an effective solution: easy to use, comfortable to wear, and uninterrupted clinically proven therapy. Babies stay secure in their parents' embrace while receiving clinically evaluated therapy. This not only reduces stress for newborns and parents but also helps hospitals save on nursing hours and incubator stays.
With trusted hospital-approved guidance, the Bilihome Remote Care App helps parents care for their newborn during treatment. It offers step-by-step instructions, safe device handling tips, and answers to common questions. Parents can log key health indicators, while healthcare staff monitor progress remotely—ensuring safe, supported home-based jaundice care.
Our solution integrates seamlessly into maternity wards, offering the only wearable, mobile phototherapy device that enables full parental contact during treatment. Unlike traditional methods that isolate newborns in incubators, our solution supports kangaroo care, reducing stress and improving bonding.
By implementing our Zero Separation Care Path, hospitals can:
For eligible newborns, our Bilihome solution provides a clinically evaluated, cost-effective alternative to hospitalization. Parents receive a small phototherapy device supported by an easy-to-use Remote Care app that offers outpatient monitoring and step-by-step guidance.
By shifting care to the home setting:
Our solution integrates seamlessly into maternity wards, offering the only wearable, mobile phototherapy device that enables full parental contact during treatment. Unlike traditional methods that isolate newborns in incubators, our solution supports kangaroo care, reducing stress and improving bonding.
By implementing our Zero Separation Care Path, hospitals can:
For eligible newborns, our Bilihome solution provides a clinically evaluated, cost-effective alternative to hospitalization. Parents receive a small phototherapy device supported by an easy-to-use Remote Care app that offers outpatient monitoring and step-by-step guidance.
By shifting care to the home setting:
Find studies on kangaroo care and jaundice, home jaundice therapy and the benefits of home therapy at the bottom of the page.
Find studies on kangaroo care and jaundice, home jaundice therapy and the benefits of home therapy at the bottom of the page.
Our jaundice Care Path for Zero Separation is not a one-size-fits-all approach. We collaborate closely with hospitals to create a tailored plan based on our blue print, ensuring smooth implementation.
By choosing bilihome, hospitals can make use of our implementation strategy, making adoption smoother, faster, and more effective.
Our lightweight, wearable phototherapy is the first of its kind, designed for comfort, ease of use and clinical effectiveness.
Our jaundice Care Path for Zero Separation is not a one-size-fits-all approach. We collaborate closely with hospitals to create a tailored plan based on our blue print, ensuring smooth implementation.
By choosing bilihome, hospitals can make use of our implementation strategy, making adoption smoother, faster, and more effective.
Our lightweight, wearable phototherapy is the first of its kind, designed for comfort, ease of use and clinical effectiveness.
Bilihome isn’t just about phototherapy—we are redefining neonatal care. Our end-to-end solution makes it easy for hospitals to implement zero-separation jaundice treatment, leading to:
Join the movement toward Zero-Separation Care. Let’s give newborns the best possible start in life—together.
Laleh Goudarzvand, Akram Dabirian, Manizheh Nourian, Hadi Jafarianesh & Mehdi Ranjbaran (2017): Comparison of conventional phototherapy and phototherapy along with Kangaroo mother care on cutaneous bilirubin of neonates with physiological jaundice, The Journal of Maternal-Fetal & Neonatal Medicine
Razie lori Kenari (MSC), Parvin Aziznejadroshan (PhD), Mohsen Haghshenas Mojaveri (MD), Karimollah Hajian-Tilaki (PhD (2020): Comparing the effect of kangaroo mother care and field massage on serum bilirubin level of term neonates with hyperbilirubinemia under phototherapy in the neonatal ward, Caspian J Intern Med 2020; 11(1):34-40.
Xiang Huang, Meiling Chen , Rongrong Fu, Wei He, Yujing He, Haojie Shentu and Suping Zhu (2023): Efficacy of kangaroo mother care combined with neonatal phototherapy in newborns with non-pathological jaundice: A meta-analysis, Frontiers in Pediatrics.
Miriam Pettersson, Mats Eriksson, Andreas Odlind, Andreas Ohlin (2022): Home phototherapy of term neonates improves parental bonding and stress: Findings from a randomised controlled trial, Acta Paediatrica. 2022; 111: 760–766.
DOI: 10.1111/apa.16231
Mona Noureldein, Grace Mupanemunda, Helen McDermott,
Katy Pettit, Richard Mupanemunda (2021): Home phototherapy for neonatal jaundice in the UK: a single-centre retrospective service evaluation and parental survey, BMJ Paediatrics Open 2021;5:e001027
Cnossen, M. C., Spaan, J., Fleischmann, M. S., van der Geest, B. A., Ista, E., Hulzebos, C. V., ... & van der Vliet–Torij, H. W. H. (2024): Home phototherapy for neonatal hyperbilirubinemia: current practices and attitudes, Pediatric Research (2024): 1-7
Miriam Pettersson, Linda Ryen, Mats Eriksson & Andreas Ohlin (2023): The cost-effectiveness of home phototherapy for hyperbilirubinemia in neonates: results from a randomized controlled trial, Acta Paediatrica. 2022; 111: 760–766.
Bilihome B.V.
Van Siburgstraat 34
3863 HW Nijkerk
The Netherlands
KVK: 75075938
VAT: NL860132109B01
Copyright © 2025 bilihome B.V.
Bilihome B.V.
Van Siburgstraat 34
3863 HW Nijkerk
The Netherlands
KVK: 75075938
VAT: NL860132109B01
Copyright © 2025 bilihome B.V.